{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00023596", "CSN": null, "TRF": "ORD_1465316_01", "MRN": "48875689", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1201337", "clinicalId": "1202707", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1465316_01", "SampleName": "US1404881.01", "Version": "0", "Sample": {"FM_Id": "ORD_1465316_01", "SampleId": "US1404881.01", "BlockId": "S111-36111B", "TRFNumber": "ORD_1465316_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_09_27", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "60", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97926", "MRN": "48875689", "FullName": "\u90b1\u66fc\u59ae", "FirstName": "Man Ni", "LastName": "Chiu", "SubmittedDiagnosis": "Atypical meningioma, Meninges", "Gender": "Female", "DOB": "1973_06_12", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Central nervous system (CNS)", "CollDate": "2022_09_14", "ReceivedDate": "2022-10-12 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Meningioma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "8", "clinicalTrialCount": "6", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "EPHB4", "isVUS": "true", "variantName": "R333H"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "G1312S"}, {"geneName": "PALB2", "isVUS": "true", "variantName": "L763F"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "A2800V"}, {"geneName": "XRCC2", "isVUS": "true", "variantName": "V39M"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "NF2", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 1446+1G>A", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 1446+1G>A"}}, "Interpretation": "Merlin, encoded by NF2, coordinates cell contact with growth signals; the inactivation of Merlin disrupts this mechanism and can lead to unrestrained growth despite cell contact (Curto and McClatchey, 2008; 17971776). Alterations such as seen here may disrupt NF2 function or expression (Laulajainen et al., 2012; 22325036, Lallemand et al., 2009; 19910496, Sherman et al., 2007; 9395247, Li et al., 2012; 22482125, Manetti et al., 2012; 23213372, Stokowski et al., 2000; 10712203, Mani et al., 2011; 21402777). NF2 is the most commonly altered gene in meningioma, and patients with germline NF2 mutations are at increased risk for meningiomas, with the lifetime risk of meningioma estimated at up to 75% (Alahmadi and Croul, 2011; 22195409, Evans, 2009; 19652604). Loss of NF2 function via mutation or loss of expression has been reported in 40_60% of sporadic meningiomas (Clark et al., 2013; 23348505, Riemenschneider et al., 2006; 17110285). NF2 mutation has been reported in 37% of meningioma samples analyzed in COSMIC (Sep 2022)(Tate et al., 2019; 30371878). One study reported that NF2 or chromosome 22 alterations occurred more frequently in high_grade (80%) vs low_grade (43%) meningioma samples analyzed (Bi et al., 2017; 28713588). NF2 mutation has been associated with monosomy 22 in sporadic meningioma, specifically in menopausal women (Tabernero et al., 2013; 24171707, Tabernero et al., 2012; 22371336). NF2 inactivating alterations may indicate sensitivity to mTOR inhibitors (Lopez_Lago et al., 2009; 19451229, James et al., 2009; 19451225, Pachow et al., 2013; 23406776, Iyer et al., 2012; 22923433). Two case studies reported clinical benefit for patients with NF2_mutated cancers, including urothelial carcinoma (Ali et al., 2015; 25630452) and metaplastic breast cancer (Ganesan et al., 2014; 25253784, Moulder et al., 2015; 25878190) treated with everolimus and temsirolimus, respectively. Loss or inactivation of NF2 may also predict sensitivity to FAK inhibitors based on clinical data in mesothelioma (Soria et al., 2016; 27733373) and meningioma (Brastianos et al., 2020; ASCO Abstract 2502) and strong preclinical data (Poulikakos et al., 2006; 16652148, Shapiro et al., 2014; 24848258, Shah et al., 2014; 24786638). Limited preclinical and clinical evidence in vestibular schwannoma suggests possible sensitivity of NF2_deficient tumors to the pan_ERBB inhibitor lapatinib (Ammoun et al., 2010; 20511180, Karajannis et al., 2012; 22844108). Similarly, on the basis of limited clinical (Subbiah et al., 2011; ASCO Abstract 2100) and preclinical (Garcia_Rendueles et al., 2015; 26359368, Ammoun et al., 2008; 18593924, Yi et al., 2011; 21481793) evidence, NF2 inactivation may predict sensitivity to MEK inhibitors, such as approved agents trametinib and cobimetinib. These and other relevant compounds are being investigated in clinical trials. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). In a Phase 2 trial of the investigational FAK inhibitor GSK2256098 for patients with meningiomas harboring NF2 mutations, 10/12 (83%) patients with Grade 1 meningioma and 8/24 (33%) patients with Grade 2 or Grade 3 disease experienced PFS lasting \u22656 months; in the Grade 1 cohort, no objective responses were observed, but 10/12 (83%) patients achieved SD, while in the Grade 2 and Grade 3 cohort, 1/24 (4%) patients achieved a PR and 14/24 (58%) patients achieved SD (Brastianos et al., 2020; ASCO Abstract 2502). Heterozygous germline NF2 loss or inactivation is associated with neurofibromatosis type 2, which results in the development of vestibular schwannomas, meningiomas, ependymomas, and ocular disturbances (Evans et al., 2011; 21358190, Lu_Emerson and Plotkin, 2009; 19898272, Asthagiri et al., 2009; 19476995). Prevalence for this disorder in the general population is estimated to be 1:25,000 (Asthagiri et al., 2009; 19476995). In the appropriate clinical context, germline testing of NF2 is recommended.", "Include": "true", "ClinicalTrialNote": "Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}, {"nctId": "NCT03203525", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). The reported incidence of MSI in meningioma has varied significantly between studies (Pykett et al., 1994; 7987826, Alvino et al., 2000; 11045018, Simon et al., 1996; 8875241, Zhu et al., 1996; 8622857, Pecina_Slaus et al., 2016; 27630299, Chen et al., 2012; 22930430, Pecina_Slaus et al., 2017; 28705114). Published data investigating the prognostic implications of MSI in meningioma are limited (PubMed, Aug 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Meningioma harbors a median TMB of 1.8 mutations per megabase (muts/Mb), and 0.9% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Grade 2 or 3 meningiomas have been associated with a higher mutation rate than Grade 1 meningiomas; meningiomas were reported to have a smaller number of somatic alterations relative to other tumor types (Brastianos et al., 2013; 23334667). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "NF2", "Alteration": "splice site 1446+1G>A", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.", "Include": "true"}, {"Gene": "NF2", "Alteration": "splice site 1446+1G>A", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.", "Include": "true"}, {"Gene": "NF2", "Alteration": "splice site 1446+1G>A", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.", "Include": "true"}, {"Gene": "NF2", "Alteration": "splice site 1446+1G>A", "Title": "A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTOR", "Locations": "Tianjin (China)", "NCTID": "NCT05125523", "Note": "Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.", "Include": "true"}, {"Gene": "NF2", "Alteration": "splice site 1446+1G>A", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, SRC, RET, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.", "Include": "true"}, {"Gene": "NF2", "Alteration": "splice site 1446+1G>A", "Title": "Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer", "StudyPhase": "PHASE 1", "Target": "VEGFA, mTOR", "Locations": "Texas", "NCTID": "NCT03203525", "Note": "Inactivation or loss of NF2 results in the dysregulation of mTOR and FAK pathway signaling. Therefore, mTOR and/or FAK inhibitors may be relevant for patients with NF2 inactivating mutations.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "17971776", "FullCitation": "Curto M, et al. Br. J. Cancer (2008) pmid: 17971776", "Include": "true"}, {"number": "1", "ReferenceId": "22325036", "FullCitation": "Laulajainen M, et al. J. Cell. Mol. Med. (2012) pmid: 22325036", "Include": "true"}, {"number": "2", "ReferenceId": "19910496", "FullCitation": "Lallemand D, et al. J. Cell. Sci. (2009) pmid: 19910496", "Include": "true"}, {"number": "3", "ReferenceId": "9395247", "FullCitation": "Sherman L, et al. Oncogene (1997) pmid: 9395247", "Include": "true"}, {"number": "4", "ReferenceId": "22482125", "FullCitation": "Li W, et al. EMBO Rep. (2012) pmid: 22482125", "Include": "true"}, {"number": "5", "ReferenceId": "23213372", "FullCitation": "Manetti ME, et al. Biol Open (2012) pmid: 23213372", "Include": "true"}, {"number": "6", "ReferenceId": "10712203", "FullCitation": "Stokowski RP, et al. Am. J. Hum. Genet. (2000) pmid: 10712203", "Include": "true"}, {"number": "7", "ReferenceId": "21402777", "FullCitation": "Mani T, et al. Mol. Cell. Biol. (2011) pmid: 21402777", "Include": "true"}, {"number": "8", "ReferenceId": "22195409", "FullCitation": "Alahmadi H, et al. Semin Diagn Pathol (2011) pmid: 22195409", "Include": "true"}, {"number": "9", "ReferenceId": "19652604", "FullCitation": "Genet. Med. (2009) pmid: 19652604", "Include": "true"}, {"number": "10", "ReferenceId": "23348505", "FullCitation": "Clark VE, et al. Science (2013) pmid: 23348505", "Include": "true"}, {"number": "11", "ReferenceId": "17110285", "FullCitation": "Riemenschneider MJ, et al. Lancet Neurol (2006) pmid: 17110285", "Include": "true"}, {"number": "12", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "13", "ReferenceId": "28713588", "FullCitation": "Bi WL, et al. NPJ Genom Med (2017) pmid: 28713588", "Include": "true"}, {"number": "14", "ReferenceId": "24171707", "FullCitation": "Tabernero M, et al. BMC Med. Genet. (2013) pmid: 24171707", "Include": "true"}, {"number": "15", "ReferenceId": "22371336", "FullCitation": "Tabernero MD, et al. Genes Chromosomes Cancer (2012) pmid: 22371336", "Include": "true"}, {"number": "16", "ReferenceId": "19451229", "FullCitation": "L\u00f3pez_Lago MA, et al. Mol. Cell. Biol. (2009) pmid: 19451229", "Include": "true"}, {"number": "17", "ReferenceId": "19451225", "FullCitation": "James MF, et al. Mol. Cell. Biol. (2009) pmid: 19451225", "Include": "true"}, {"number": "18", "ReferenceId": "23406776", "FullCitation": "Pachow D, et al. Clin. Cancer Res. (2013) pmid: 23406776", "Include": "true"}, {"number": "19", "ReferenceId": "22923433", "FullCitation": "Iyer G, et al. Science (2012) pmid: 22923433", "Include": "true"}, {"number": "20", "ReferenceId": "25630452", "FullCitation": "Ali SM, et al. Eur. Urol. (2015) pmid: 25630452", "Include": "true"}, {"number": "21", "ReferenceId": "25253784", "FullCitation": "Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784", "Include": "true"}, {"number": "22", "ReferenceId": "25878190", "FullCitation": "Moulder S, et al. Ann. Oncol. (2015) pmid: 25878190", "Include": "true"}, {"number": "23", "ReferenceId": "27733373", "FullCitation": "Soria JC, et al. Ann. Oncol. (2016) pmid: 27733373", "Include": "true"}, {"number": "24", "ReferenceId": "16652148", "FullCitation": "Poulikakos PI, et al. Oncogene (2006) pmid: 16652148", "Include": "true"}, {"number": "25", "ReferenceId": "24848258", "FullCitation": "Shapiro IM, et al. Sci Transl Med (2014) pmid: 24848258", "Include": "true"}, {"number": "26", "ReferenceId": "24786638", "FullCitation": "Shah NR, et al. Gynecol. Oncol. (2014) pmid: 24786638", "Include": "true"}, {"number": "27", "ReferenceId": "20511180", "FullCitation": "Ammoun S, et al. Neuro_oncology (2010) pmid: 20511180", "Include": "true"}, {"number": "28", "ReferenceId": "22844108", "FullCitation": "Karajannis MA, et al. Neuro_oncology (2012) pmid: 22844108", "Include": "true"}, {"number": "29", "ReferenceId": "26359368", "FullCitation": "Garcia_Rendueles ME, et al. Cancer Discov (2015) pmid: 26359368", "Include": "true"}, {"number": "30", "ReferenceId": "18593924", "FullCitation": "Ammoun S, et al. Cancer Res. (2008) pmid: 18593924", "Include": "true"}, {"number": "31", "ReferenceId": "21481793", "FullCitation": "Yi C, et al. Cancer Cell (2011) pmid: 21481793", "Include": "true"}, {"number": "32", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "33", "ReferenceId": "21358190", "FullCitation": "Evans GR, et al. Adv. Otorhinolaryngol. (2011) pmid: 21358190", "Include": "true"}, {"number": "34", "ReferenceId": "19898272", "FullCitation": "Lu_Emerson C, et al. Rev Neurol Dis (2009) pmid: 19898272", "Include": "true"}, {"number": "35", "ReferenceId": "19476995", "FullCitation": "Asthagiri AR, et al. Lancet (2009) pmid: 19476995", "Include": "true"}, {"number": "36", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "37", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "38", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "39", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "40", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "41", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "42", "ReferenceId": "7987826", "FullCitation": "Pykett MJ, et al. Cancer Res. (1994) pmid: 7987826", "Include": "true"}, {"number": "43", "ReferenceId": "11045018", "FullCitation": "Alvino E, et al. Neurol. Res. (2000) pmid: 11045018", "Include": "true"}, {"number": "44", "ReferenceId": "8875241", "FullCitation": "Simon M, et al. Genes Chromosomes Cancer (1996) pmid: 8875241", "Include": "true"}, {"number": "45", "ReferenceId": "8622857", "FullCitation": "Zhu J, et al. Oncogene (1996) pmid: 8622857", "Include": "true"}, {"number": "46", "ReferenceId": "27630299", "FullCitation": "Pe\u0107ina_\u0160laus N, et al. Anticancer Res. (2016) pmid: 27630299", "Include": "true"}, {"number": "47", "ReferenceId": "22930430", "FullCitation": "Chen MN, et al. Genet. Mol. Res. (2012) pmid: 22930430", "Include": "true"}, {"number": "48", "ReferenceId": "28705114", "FullCitation": "Pe\u0107ina_\u0160laus N, et al. Tumour Biol. (2017) pmid: 28705114", "Include": "true"}, {"number": "49", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "50", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "51", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "52", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "53", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "54", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "55", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "56", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "57", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "58", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "59", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "60", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "61", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "62", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "63", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "64", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "65", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "66", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "67", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "68", "ReferenceId": "23334667", "FullCitation": "Brastianos PK, et al. Nat. Genet. (2013) pmid: 23334667", "Include": "true"}, {"number": "69", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "70", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "71", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "72", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "73", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "74", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "75", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "76", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "77", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "78", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "79", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "80", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_10_04 19:29:59", "OpName": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "987x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain meningioma", "flowcell_analysis": "2000023828", "gender": "female", "pathology_diagnosis": "Meningioma, D32.9", "percent_tumor_nuclei": "60", "pipeline_version": "v3.14.0", "purity_assessment": "77.9", "specimen": "ORD_1465316_01*US1404881.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1465316_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Central nervous system (CNS)", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "982.17", "name": "SQ_US1404881.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.6524", "cds_effect": "1446+1G>A", "depth": "466", "equivocal": "false", "functional_effect": "splice", "gene": "NF2", "percent_reads": "65.24", "position": "chr22:30070931", "protein_effect": "splice site 1446+1G>A", "status": "likely", "strand": "+", "transcript": "NM_000268", "dna_evidence": {"sample": "SQ_US1404881.01_1"}}, {"allele_fraction": "0.4683", "cds_effect": "115G>A", "depth": "758", "equivocal": "false", "functional_effect": "missense", "gene": "XRCC2", "percent_reads": "46.83", "position": "chr7:152357792", "protein_effect": "V39M", "status": "unknown", "strand": "_", "transcript": "NM_005431", "dna_evidence": {"sample": "SQ_US1404881.01_1"}}, {"allele_fraction": "0.4929", "cds_effect": "2289G>C", "depth": "1063", "equivocal": "false", "functional_effect": "missense", "gene": "PALB2", "percent_reads": "49.29", "position": "chr16:23641186", "protein_effect": "L763F", "status": "unknown", "strand": "_", "transcript": "NM_024675", "dna_evidence": {"sample": "SQ_US1404881.01_1"}}, {"allele_fraction": "0.4969", "cds_effect": "3934G>A", "depth": "491", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "49.69", "position": "chr13:110434467", "protein_effect": "G1312S", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1404881.01_1"}}, {"allele_fraction": "0.4897", "cds_effect": "998G>A", "depth": "580", "equivocal": "false", "functional_effect": "missense", "gene": "EPHB4", "percent_reads": "48.97", "position": "chr7:100417478", "protein_effect": "R333H", "status": "unknown", "strand": "_", "transcript": "NM_004444", "dna_evidence": {"sample": "SQ_US1404881.01_1"}}, {"allele_fraction": "0.4818", "cds_effect": "8399C>T", "depth": "936", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "48.18", "position": "chr1:16261134", "protein_effect": "A2800V", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1404881.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}